Illumina Postpones Q4, FY 2011 Earnings Release to Mull Over Roche's Hostile Bid | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina today postponed the release of its fourth-quarter and full-year 2011 financial results as its board reviews Roche's $5.7 million hostile bid for the San Diego-based next-generation sequencing and microarray firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.